StemRIM (TYO:4599)
123.00
+1.00 (0.82%)
Nov 18, 2026, 10:19 AM JST
StemRIM Company Description
StemRIM, a biotechnology company, researches and develops regeneration-inducing medicine in Japan and internationally.
The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, acute ischemic stroke, cerebral infarction, myocardial infarction/cardiomyopathy, chronic liver disease, and knee osteoarthritis.
It also develops TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair, as well as SR-GT1, a gene therapy for the treatment of epidermolysis bullosa.
The company was incorporated in 2006 and is headquartered in Ibaraki, Japan.
StemRIM
| Country | Japan |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 48 |
| CEO | Masatsune Okajima |
Contact Details
Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan | |
| Phone | 81 72 648 7152 |
| Website | stemrim.com |
Stock Details
| Ticker Symbol | 4599 |
| Exchange | Tokyo Stock Exchange |
| Fiscal Year | August - July |
| Reporting Currency | JPY |
| ISIN Number | JP3399690001 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Masatsune Okajima | Chief Executive Officer |